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overall goal is to provide a cure. If that is not possible,
we look to maximize disease-free survival, improve
treatment response, and help patients maintain the best
quality of life (QOL) possible. The subject of these
symposia—the clinical signiﬁcance and evolving
management of anemia in patients with cancer—is
an important factor in optimizing patients’ well-being
during the period of cancer treatment.
Anemia in cancer is often seen at presentation and is
exacerbated by radiotherapy and chemotherapy [1–4]. A
reduction in the oxygen-carrying capacity of the blood
is one of several interconnected pathogenetic factors
that contribute to the development of tumor hypoxia, a
condition involving an imbalance between the supply
and consumption of oxygen [5]. Hemoglobin (Hb) levels
<12 g/dL appear to be a threshold for development of
tumor hypoxia [6]. Other major mechanisms contribut-
ing to the emergence of hypoxia are structural and
functional abnormalities in the tumor microvasculature
and an increase in diﬀusion distances so that cells
farther away from the nutritive blood vessel receive too
little oxygen [7,8]. Clinically relevant areas of hypoxia
are detected in approximately 50% of solid tumors
regardless of their size, stage, and histological features.
Numerous clinical and experimental studies have
demonstrated that tumor hypoxia can profoundly aﬀect
the clinical course of cancer and the response to
treatment [5,9–11]. Tumor hypoxia appears to rendertumor cells more resistant to sparsely ionizing
radiation therapy and some forms of chemotherapy. It
also can modulate the proliferation and cell cycle
position of tumor cells and, consequently, the number
of cells destroyed by therapy [5,7,8]. In addition,
through genomic changes and clonal selection, hypoxia
can promote aggressive tumor growth and metastatic
disease [5].
Studies concerning the relationship between Hb levels
and cancer pathophysiology suggest that anemia is cor-
related with a poor treatment response and prognosis
[12]. Uncorrected anemia has been shown to be
associated with poor outcome in several hematologic
malignancies (non-Hodgkin’s lymphoma, mantle cell
lymphoma, Hodgkin’s disease, acute myeloid leukemia,
chronic lymphocytic leukemia, multiple myeloma) and
solid tumors (non-small cell lung cancer, ovarian can-
cer, renal carcinoma, head and neck cancer). Anemia
also appears to independently inﬂuence treatment
response in patients with acute myeloid leukemia and in
those with mantle cell lymphoma, and possibly in those
with relapsing ovarian cancer [13]. These ﬁndings,
although suggestive, must be interpreted with caution,
since they are derived almost exclusively from retro-
spective analyses of medical records.
Hemoglobin levels can also profoundly aﬀect the
patient’s well-being, regardless of tumor type or prog-
nosis. The development of validated QOL measures
(especially the FACT-An) has enabled researchers to
explore the impact of anemia on patients’ everyday
functioning in a number of recent clinical studies [14–
16]. Profound, pervasive fatigue, a common symptom
of anemia, aﬀects up to 78% of patients with cancer
[17]. Fatigue can interfere with every aspect of a
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economic—leading to signiﬁcant functional impairment
and a deteriorating QOL. Other symptoms of anemia,
such as dyspnea, weakness, and chest pain, can produce
an additional impact on patients’ lives.
The recently increased appreciation of the impact of
anemia-related symptoms has led to a series of clinical
trials evaluating the eﬃcacy of recombinant human
erythropoietin (rHuEPO, epoetin alfa) in correcting
anemia and improving QOL in patients with a variety of
solid tumors and nonmyeloid hematologic malig-
nancies. As three of these trials demonstrated, epoetin
alfa is eﬀective in increasing Hb levels in approximately
60 to 70% of patients. Further, the hematologic eﬀect of
epoetin alfa is achieved rapidly, with Hb levels increas-
ing by 1 g/dl at 4 weeks and 2 g/dl at 8 weeks [14–
16]. The increase in Hb levels is signiﬁcantly correlated
with less fatigue, as assessed by speciﬁc measures of
cancer-related fatigue (FACT-An) and improved overall
QOL; epoetin alfa therapy has also been associated with
a reduced need for transfusions [14–16,18,19]. Long-
itudinal multivariate regression analysis has demon-
strated that these beneﬁts are maintained after
controlling for a wide array of patient-, disease-, and
treatment-related factors that are also likely to inﬂuence
QOL [20]. The maximal incremental improvements in
QOL scores were observed when Hb levels increased
from 11 to 12 g/dl (range 11 to 13 g/dl) [21,22]. The
clinical relevance of the statistically signiﬁcant changes
in FACT-An QOL scores among anemic cancer patients
treated with epoetin alfa has been conﬁrmed retro-
spectively by reference to population normative data
[23].
Because of the manifold implications of anemia in
cancer and the demonstrated beneﬁts of anemia correc-
tion, the American Society of Hematology and the
American Society of Clinical Oncology (ASH/ASCO),
as well as the National Comprehensive Cancer Network
(NCCN), have developed recommendations for anemia
management. ASH/ASCO recommends therapy with
epoetin alfa 150–300 IU/kg TIW for patients with
cancer-related anemia who have an Hb level 410 g/dl
and, based on clinical circumstance, for patients with
Hb <12 g/dl [24]. An alternate dosing regimen of
40 000–60 000 IU QW, based on common clinical prac-
tice, is also noted. The NCCN recommends therapy
with epoetin alfa 150–300 IU/kg TIW or 40 000–60 000
IU QW during radiotherapy or chemotherapy for ane-
mic cancer patients [25]. This approach is particularly
recommended for patients whose Hb levels are <11 g/dl,
since the supporting clinical data are primarily derived
from studies involving patients with moderate anemia.
The QW epoetin alfa dose (40 000–60 000 IU) is
recommended based on data from prospective clinical
trials in which this regimen resulted in an increase in Hb
level of 1.0 g/dL at 4 weeks and 2 g/dL at 8 weeks
[15,26,27]. The magnitude and rapidity of the Hbincrease in these studies is similar to that reported in
trials involving the TIW regimen [16]. In addition, this
QW epoetin alfa dosing regimen is commonly used in
the United States with both eﬃcacy and convenience
[28]. Encouraging results have also been obtained from
small studies evaluating more ﬂexible front-loading
dosing regimens to optimize Hb increase and response
time while minimizing frequency of administration
[29,30].
Although the data supporting use of epoetin alfa
therapy are strongest concerning patients with estab-
lished anemia, there is a growing body of evidence that
cancer patients whose Hb level is 12 g/dl at the start
of radiotherapy or chemotherapy may also beneﬁt. Pre-
liminary results of two small studies indicate that early
intervention with epoetin alfa in breast cancer patients
receiving adjuvant or neoadjuvant chemotherapy eﬀec-
tively maintains normal Hb levels while stabilizing or
improving QOL [31,32]. A most intriguing avenue of
study remains the eﬀect of improved or maintained Hb
levels with epoetin alfa on survival. Studies that eval-
uated survival diﬀerences in anemic patients who were
treated versus those not treated with epoetin alfa indi-
cate that higher hemoglobin levels are indicative of
longer survival [16,33]. When viewed together with the
results of studies demonstrating the negative impact of
anemia on treatment outcomes and survival [12,34],
there is justiﬁcation for strongly recommending that
eﬀective anemia treatment be an integral part of overall
cancer management.
Although the beneﬁts of epoetin alfa have most
clearly been demonstrated in the treatment of anemia,
recent research in various animal models suggests that
the drug’s ability to cross the blood-brain barrier may
render epoetin alfa neuroprotective under a variety of
hypoxic and traumatic conditions [35]. In the rat model
of ischemic stroke, for example, tissue damage was
signiﬁcantly reduced when epoetin alfa was adminis-
tered up to 24 h before (P<0.01) or up to 6 h after
(P<0.05) stroke induction [36]. In experimental transient
spinal cord ischemic injury induced in rabbits, epoetin
alfa was found to be protective against motor neuron
apoptosis and neurological disability [37]. Other studies
in rodent models provide a basis for exploring the
potential usefulness of epoetin alfa for such CNS-spe-
ciﬁc illnesses as epilepsy, encephalomyelitis, Parkinson’s
disease, Alzheimer’s disease, and amyotropic lateral
sclerosis [36].
In conclusion, the provision of hematopoietic support
for patients with cancer has evolved considerably in the
past decade and will probably change more in the near
term, as the need for it becomes better appreciated and
treatment strategies are optimized. Epoetin alfa is
known to increase Hb levels, improve QOL, and reduce
the need for transfusions in patients with a variety of
malignancies. Ongoing research may help to clarify42 R. Bugat, P. Vaupel / EJC Supplements Vol 2 No. 2 (2004) 41–44
optimal dosage regimens and identify the best interven-
tion points for the initiation of epoetin alfa therapy in
various patient populations. Currently available data
indicate the need for additional studies to assess whether
the beneﬁts of epoetin alfa extend to improved treatment
response and longer survival in patients with cancer, as
well as whether epoetin alfa will improve the prognosis
for those with a variety of CNS-speciﬁc illnesses.References
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